Search by Drug Name or NDC

    NDC 50222-0346-92 Adbry 150 mg/mL Details

    Adbry 150 mg/mL

    Adbry is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by LEO Pharma Inc.. The primary component is TRALOKINUMAB.

    Product Information

    NDC 50222-0346
    Product ID 50222-346_5b709bae-6a5c-4a83-8bb1-83c8069d8086
    Associated GPIs 9027308045E520
    GCN Sequence Number 082945
    GCN Sequence Number Description tralokinumab-ldrm SYRINGE 150 MG/ML SUBCUT
    HIC3 V4G
    HIC3 Description INTERLEUKIN-13 (IL-13) INHIBITORS, MAB
    GCN 51749
    HICL Sequence Number 047741
    HICL Sequence Number Description TRALOKINUMAB-LDRM
    Brand/Generic Brand
    Proprietary Name Adbry
    Proprietary Name Suffix n/a
    Non-Proprietary Name tralokinumab-ldrm
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, SOLUTION
    Route SUBCUTANEOUS
    Active Ingredient Strength 150
    Active Ingredient Units mg/mL
    Substance Name TRALOKINUMAB
    Labeler Name LEO Pharma Inc.
    Pharmaceutical Class Interleukin-13 Antagonist [EPC], Interleukin-13 Antagonists [MoA]
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA761180
    Listing Certified Through 2024-12-31

    Package

    NDC 50222-0346-92 (50222034692)

    NDC Package Code 50222-346-92
    Billing NDC 50222034692
    Package 2 SYRINGE, GLASS in 1 CARTON (50222-346-92) / 1 mL in 1 SYRINGE, GLASS (50222-346-91)
    Marketing Start Date 2022-01-02
    NDC Exclude Flag N
    Pricing Information N/A